Revenues during 2023 reached NIS 356 million, alongside an Adjusted EBITDA1 of NIS 61 million , as compared to an Adjusted EBITDA of NIS 51 million in our preliminary results.
The Company’s.
Revenues for H2 2023 were affected by damages caused by the terrorist attack on October 7, 2023 and the war in Gaza. However, InterCure it is entitled to full compensation from the Israeli.
InterCure : Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBIDTA of over NIS 50 million - Form 6-K -April 01, 2024 at 08:43 am EDT marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.